Skip to main content

Doing Life Sciences Deals in 2024 - Licensing, M&A, and More

Hosted by Mintz and the Life Sciences Sector and the Boston Chapter of Licensing Executives Society USA and Canada


Date: April 11, 2024

Location: Boston

Join us for two informative panels that will discuss structuring life sciences transactions and key issues for biopharma licensing deals. 


Structuring Your Life Sciences Transaction: Licensing vs. M&A vs. Asset Sale

Topics to be covered include: 

  • Key considerations when structuring your life sciences deal
  • Deal trends
  • How to determine when you should do a M&A deal, a license, or an asset sale?
  • Strategies for doing deals with big pharma
  • What does big pharma look for in a deal structure?
  • Is licensing a way to a M&A deal with a big pharma partner?


  • Moderator - Cheryl Reicin, International Chair, Life Sciences, Mintz
  • Jeff Caravella, Business Development, Interventional Oncology, Johnson & Johnson
  • Andy Meyerson, Managing Director, Locust Walk
  • Veronica Miller, Executive Director, Business Development, Astria Therapeutics, Inc.
  • Jonathan Kiburz, Vice President, Business Development Transactions, GSK 


Key Issues for Your Biopharma Licensing Deal – IP, Scientific Diligence, and More

Topics to be covered include: 

  • Key non-economic issues for your biopharma licensing deal
  • IP deal diligence – What does the IP diligence process look like, and how can a biotech satisfy a big pharma’s IP asks?
  • What does a “good” diligence process look like? How do you run an efficient and productive diligence process?
  • Scientific rigor – How does a big pharma evaluate your science?
  • How do these key issues play into your license agreement?
  • How should you time your licensing deal with your data readout?


  • Moderator - Adam Falconi, Attorney, Mintz
  • Fanny Cavalié, Chief Strategy and Business Operations Officer, Foghorn Therapeutics
  • Bea Gadala-Maria, Senior Director, Business Development at AstraZeneca - Early Stage Oncology Transactions
  • Imran Nasrullah, Vice President & Head, Collaborate2Cure Hub, US, Business Development & Licensing, Bayer Pharmaceuticals


Register for Event


Cheryl Reicin headshot

Cheryl V. Reicin


Cheryl V. Reicin is the International Chair of Mintz’s Life Sciences practice and a trusted advisor to life sciences companies and significant investors in the US, Canada, and countries around the globe. She represents biotechnology, medical device, and health technology companies at all stages of their development as well as venture capitalists, investment banks, and academic medical centers.
Adam Falconi Professional Headshot

Adam Falconi


Adam Falconi is an Associate at Mintz who focuses his practice on corporate law, financing, and technology transactions in the life sciences and health technology industries. He represents a range of life science and health care companies, as well as venture capital and private equity funds.